2 December 2019 - The prices of newly approved cancer drugs have risen over the past decades. 

A key policy question is whether the clinical gains offered by these drugs in treating specific cancer indications justify the price increases.

This study evaluated the price per median and mean life year gained among newly approved cancer therapies from 1995 to 2017.

Read Value in Health article